The Louisiana Supreme Court has ruled that Johnson & Johnson’s Janssen subsidiary doesn’t owe $257.7 million for alleged misconduct in marketing the antipsychotic drug Risperdal as well as $73 million in attorney fees and court costs.
Justice Greg G. Guidry, writing for the majority, said the verdict needed to be reversed because no evidence was presented that any defendant made or attempted to make a fraudulent claim for payment against any of Louisiana’s medical assistance programs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
